Category - Markets

William Blair launched coverage of AxoGen (NASDAQ:AXGN) with an “outperform” rating. The stock closed at $26.65 on Feb. 2. AxoGen is a global leader in the peripheral nerve repair and regeneration industry, and sells a...

Roth Capital Partners initiated coverage of Epizyme (NASDAQ:EPZM) with a “buy” rating and $24 price target. The stock closed at $16.15 on Jan. 31. Analyst Jotin Marango writes that during the past five years in the...

Ladenburg Thalmann initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $25.50 price target. The stock closed at $12.07 on Jan. 26. Zynerba is developing two clinical-stage synthetic...

Stifel launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with a “buy” rating and a $32 target price. The stock closed at $19.23 on Jan. 26. Protagonist is leveraging its proprietary peptide technology platform...

Maxim Group initiated coverage of Atossa Genetics (NASDAQ:ATOS) with a “buy” rating and 12-month price target of $2. The stock closed at 33 cents on Jan. 25. Atossa is developing an oral formulation of endoxifen for...

RBC Dominion Securities downgraded TSO3 (TSX:TOS) to “sector perform” from “outperform” and slashed its price target to $2 from $4.25 after the company entered into a new co-distribution agreement with Getinge to sell...

Ladenburg Thalmann initiated coverage of Flex Pharma (NASDAQ:FLKS) with a “buy” rating and $12 price target. The stock closed at $4.02 on Jan. 24. Flex is leveraging its research in muscle cramping as a disorder of...

Canaccord Genuity resumed coverage of Neovasc (NASDAQ:NVCN) with a “buy” rating and price target of $1.05. The stock closed at 53 cents on Jan. 18. Analyst Jason Mills writes that Neovasc recently reported acceleration...

Mackie Research Capital resumed coverage of WeedMD (TSXV:WMD) and raised its price target to $4 from $3 after the company completed a $34.5-million offering of units. The stock closed at $2.60 on Jan. 16. WeedMD is a...

Ladenburg Thalmann downgraded Aradigm (NASDAQ:ARDM) to “neutral” from “buy” and removed its previous $10 price target. The stock closed at $3.42 on Jan. 16. On Jan 11, the Antimicrobial Drugs Advisory Committee of the...